İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 1 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.03570261 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 23.59 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 2 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.071402 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 47.18 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 3 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.04073661 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 39.80 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 4 mg ut guanfacini hydrochloridum 4.56 mg, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.054581 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 53.07 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - adhd nei bambini e negli adolescenti (6-17 anni) - synthetika

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

takeda pharma a/s - darvadstrocel - fistola rettale - immunosoppressori - alofisel è indicato per il trattamento del complesso fistole perianale, in pazienti adulti con non attivo/moderatamente attivo del lume della malattia di crohn, quando fistole hanno mostrato una risposta inadeguata ad almeno uno convenzionale o terapia biologica. alofisel deve essere utilizzato dopo condizionata di fistola.

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einem fertigpen - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - colite ulcerosa, morbo di crohn - biotechnologika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einer fertigspritze - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - colite ulcerosa, morbo di crohn - biotechnologika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 30 mg, lactosum monohydricum 56.06 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 126 - 189 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 90 mg, lactosum monohydricum 168.17 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 378 - 567 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

İsviçre - İtalyanca - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 180 mg, lactosum monohydricum 336.33 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 756 - 1134 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika